The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT

Core Points - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the company's gene therapy product, ELEVIDYS [1] - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, during which significant safety risks and adverse events associated with ELEVIDYS were allegedly not disclosed [1] - Shareholders are encouraged to register for participation in the class action by the deadline of August 25, 2025, to potentially be appointed as lead plaintiffs [1] Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements regarding the safety of ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [1] - Specific allegations include failure to disclose significant safety risks, inadequate trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [1] - The misleading statements are said to have artificially inflated the company's stock value, leading to investor losses [2] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are advised to register for the class action to receive updates and monitor the case [1] - There is no cost or obligation for shareholders to participate in the case [1]